Drugs /

autologous cmv-pp65-shlamp-1 mrna loaded dendritic cell vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A cancer cell vaccine consisting of autologous dendritic cells pulsed with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion construct with a short peptide chimeric antigen from lysosome-associated membrane protein 1 (shLAMP-1), with potential antineoplastic and immunostimulatory activities. Upon vaccination, the autologous CMV-pp65-shLAMP-1 vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of shLAMP-1 may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped sub-viral particle of CMV and is expressed in certain tumor types.

Clinical Trials

View Clinical Trials for autologous cmv-pp65-shlamp-1 mrna loaded dendritic cell vaccine

Autologous cmv-pp65-shlamp-1 mrna loaded dendritic cell vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating autologous cmv-pp65-shlamp-1 mrna loaded dendritic cell vaccine, 1 is phase 2 (1 open).

Glioblastoma is the most common disease being investigated in autologous cmv-pp65-shlamp-1 mrna loaded dendritic cell vaccine clinical trials [2].

Drug Details

Synonyms [2]:
pp65-shlamp-1 mrna dcs, autologous shlamp-1-pp65-dcs, autologous shlamp-1-pp65-dc vaccine, autologous shlamp-1-pp65 mrna-pulsed dc vaccine, autologous pp65-shlamp-1 dc vaccine
NCIT ID [1]:
C158522

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.